Arvinas’ (ARVN) “Neutral” Rating Reiterated at Wedbush

Wedbush reissued their neutral rating on shares of Arvinas (NASDAQ:ARVN) in a research report sent to investors on Thursday morning,RTT News reports. The firm currently has a $9.00 price target on the stock. Wedbush also issued estimates for Arvinas’ Q1 2026 earnings at ($0.63) EPS and Q2 2026 earnings at ($0.65) EPS.

ARVN has been the subject of several other reports. Barclays boosted their target price on shares of Arvinas from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday. Stephens lowered their target price on shares of Arvinas from $16.00 to $14.00 and set an “overweight” rating on the stock in a research report on Thursday, September 18th. Bank of America cut Arvinas from a “buy” rating to a “neutral” rating and set a $10.00 price target for the company. in a research report on Wednesday, September 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Arvinas in a research note on Wednesday, October 8th. Finally, HC Wainwright cut their price objective on Arvinas from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Eleven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $16.34.

Arvinas Trading Up 6.3%

NASDAQ:ARVN opened at $10.63 on Thursday. The business’s fifty day moving average price is $8.83 and its 200 day moving average price is $7.91. The firm has a market capitalization of $682.66 million, a price-to-earnings ratio of -13.12 and a beta of 2.38. Arvinas has a 1-year low of $5.90 and a 1-year high of $28.70.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Wednesday, November 5th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.27. Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.The company had revenue of $41.90 million for the quarter, compared to the consensus estimate of $29.36 million. During the same quarter in the prior year, the company earned ($0.68) EPS. The firm’s quarterly revenue was down 59.1% on a year-over-year basis. Equities analysts forecast that Arvinas will post -3.81 earnings per share for the current year.

Arvinas declared that its board has authorized a stock repurchase program on Wednesday, September 17th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the company to reacquire up to 17.9% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In other Arvinas news, Director Briggs Morrison bought 30,000 shares of the stock in a transaction on Monday, September 22nd. The shares were purchased at an average price of $7.57 per share, with a total value of $227,100.00. Following the acquisition, the director directly owned 76,021 shares of the company’s stock, valued at $575,478.97. This represents a 65.19% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.73% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arvinas

Hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Arvinas by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after acquiring an additional 2,122 shares during the last quarter. Oxford Asset Management LLP boosted its stake in Arvinas by 15.5% during the 2nd quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock worth $123,000 after acquiring an additional 2,242 shares during the last quarter. Nebula Research & Development LLC grew its holdings in Arvinas by 3.9% during the second quarter. Nebula Research & Development LLC now owns 76,747 shares of the company’s stock valued at $565,000 after purchasing an additional 2,910 shares during the period. AlphaQuest LLC increased its stake in Arvinas by 18.7% in the second quarter. AlphaQuest LLC now owns 19,573 shares of the company’s stock valued at $144,000 after purchasing an additional 3,086 shares in the last quarter. Finally, Woodline Partners LP raised its holdings in Arvinas by 0.5% in the first quarter. Woodline Partners LP now owns 695,945 shares of the company’s stock worth $4,886,000 after purchasing an additional 3,212 shares during the period. 95.19% of the stock is owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.